Solara Active Pharma Sciences quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	417	314	+33.1%
EBITDA	76.8	34.7	+121.2%
EBITDA margin	18.4%	11.1%	+7.3 pts
Profit before tax	28.5	−10.1	—
Net profit	28.5	−10.1	—
EPS	₹5.92	−₹2.36	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	417	382	387	349	314	319	273	300	347	363	299	249	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.5	2.7	4.7	0.0	0.5	1.0	6.0	1.5	0.3	0.6	1.7	0.5
	418	384	392	349	314	320	279	302	347	364	301	249
	218	181	182	176	150	165	144	144	157	137	158	158
	2.3	0.9	0.8	2.7	0.0	0.0	5.1	0.0	0.7	0.0	0.2	0.3
	−6.4	14.8	14.4	8.2	4.3	−18.7	−30.6	−9.1	14.3	64.5	1.5	57.5
	57.6	56.1	55.5	55.2	54.9	53.6	52.3	51.7	52.7	55.0	56.0	62.6
	17.8	21.6	27.6	22.5	20.8	23.9	29.1	26.5	28.3	30.9	30.7	25.4
	26.6	26.7	26.0	25.6	24.5	23.6	24.3	24.5	25.3	25.1	25.3	26.0
	69.2	67.2	76.7	69.8	70.0	62.0	57.3	56.1	61.0	65.0	73.7	132
	385	368	383	360	324	310	281	294	339	378	346	462
	76.8	62.0	57.7	37.3	34.7	57.0	45.4	57.7	61.3	41.9	9.8	−162
	50.2	35.3	31.6	11.8	10.2	33.4	21.1	33.1	36.0	16.9	−15.5	−188
Profit
	33.0	16.3	8.7	−10.7	−10.1	10.5	−2.1	8.1	8.0	−13.5	−44.5	−213
	−4.5	0.0	0.9	−6.8	0.0	0.0	0.0	0.0	0.0	0.0	−122	−62.8
	28.5	16.3	9.6	−17.4	−10.1	10.5	−2.1	8.1	8.0	−13.5	−167	−275
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	88.8	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	88.8	0.0
	28.5	16.3	9.6	−17.4	−10.1	10.5	−2.1	8.1	8.0	−13.5	−255	−275
	28.5	16.3	9.6	−17.4	−10.1	10.5	−2.1	8.1	8.0	−13.5	−255	−275
	0.1	−0.1	0.5	1.6	0.8	−0.0	−0.6	−0.1	1.7	−0.0	0.3	−0.0
	28.6	16.3	10.1	−15.9	−9.3	10.5	−2.7	8.0	9.7	−13.5	−255	−275
	28.5	16.3	9.6	−17.4	−10.1	10.5	−2.1	8.1	—	−13.5	−255	−275
	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	—	0.0	−0.1	0.0
Per share
	₹5.92	₹3.52	₹2.20	−₹3.98	−₹2.36	₹2.46	−₹0.93	₹2.03	₹2.54	−₹3.50	−₹70.93	−₹76.49
	₹5.92	₹3.52	₹2.20	−₹3.98	−₹2.36	₹2.46	−₹0.93	₹2.03	₹2.54	−₹3.50	−₹70.93	−₹76.49
Other comprehensive income — detail
	0.1	−0.1	0.5	1.6	0.8	−0.0	−0.6	—	—	—	—	—
	0.2	—	0.7	1.6	1.0	—	−0.6	0.0	1.7	—	0.3	0.0
	−0.0	−0.1	−0.2	−0.1	−0.2	—	0.0	−0.1	−0.0	−0.0	−0.0	−0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—
	28.6	16.3	10.1	−15.9	−9.3	10.5	−2.7	8.0	—	−13.5	−255	−275
	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	—	0.0	−0.1	0.0
Per share — as-filed variants
	₹5.92	₹3.52	₹2.20	−₹3.98	−₹2.36	₹2.46	−₹0.93	₹2.03	₹2.54	−₹3.50	−₹70.93	−₹76.49
	₹5.92	₹3.52	₹2.20	−₹3.98	−₹2.36	₹2.46	−₹0.93	₹2.03	₹2.54	−₹3.50	−₹70.93	−₹76.49
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	204	185	190	162	160	173	155	165	175	162	139	33.2
	48.8%	48.5%	49.0%	46.5%	50.9%	54.1%	56.7%	55.1%	50.5%	44.5%	46.6%	13.4%
Adjusted (ex-exceptional items) — derived
	33.0	16.3	8.7	−10.7	−10.1	10.5	−2.1	8.1	8.0	−13.5	−44.5	−213
	−4.5	0.0	0.9	−6.8	0.0	0.0	0.0	0.0	0.0	0.0	−122	−62.8
	33.0	16.3	8.7	−10.7	−10.1	10.5	−2.1	8.1	8.0	−13.5	−133	−213
	₹6.86	₹3.52	₹2.00	−₹2.44	−₹2.36	₹2.46	−₹0.93	₹2.03	₹2.54	−₹3.50	−₹37.00	−₹59.05

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	248.7	299.4	363.5	347.0	300.3	273.0	319.2	313.5	349.0	387.3	381.6	417.3
Other Income	0.5	1.7	0.6	0.3	1.5	6.0	1.0	0.5	0.0	4.7	2.7	0.5
Total Income	249.2	301.1	364.1	347.3	301.8	279.0	320.1	314.0	349.0	392.0	384.3	417.9
Expenses
+ Cost of Materials Consumed	157.8	158.4	137.1	156.9	144.0	143.7	165.1	149.7	175.7	182.2	180.8	217.8
+ Purchases of Stock-in-Trade	0.3	0.2	0.0	0.7	0.0	5.1	0.0	0.0	2.7	0.8	0.9	2.3
+ Changes in Inventories	57.5	1.5	64.5	14.3	-9.1	-30.6	-18.7	4.3	8.2	14.4	14.8	-6.4
+ Employee Benefit Expense	62.6	56.0	55.0	52.7	51.7	52.3	53.6	54.9	55.2	55.5	56.1	57.6
+ Finance Costs	25.4	30.7	30.9	28.3	26.5	29.1	23.9	20.8	22.5	27.6	21.6	17.8
+ Depreciation & Amortisation	26.0	25.3	25.1	25.3	24.5	24.3	23.6	24.5	25.6	26.0	26.7	26.6
+ Other Expenses	132.3	73.7	65.0	61.0	56.1	57.3	62.0	70.0	69.8	76.7	67.2	69.2
Total Expenses	461.8	345.6	377.5	339.3	293.7	281.1	309.6	324.1	359.7	383.2	368.0	384.9
EBITDA	-161.7	9.8	41.9	61.3	57.7	45.4	57.0	34.7	37.3	57.7	62.0	76.8
EBIT	-187.7	-15.5	16.9	36.0	33.1	21.1	33.4	10.2	11.8	31.6	35.3	50.2
Profit
PBT before Exceptional Items	-212.6	-44.5	-13.5	8.0	8.1	-2.1	10.5	-10.1	-10.7	8.7	16.3	33.0
+ Exceptional Items	-62.8	-122.2	0.0	0.0	0.0	0.0	0.0	0.0	-6.8	0.9	0.0	-4.5
Pretax Income	-275.3	-166.7	-13.5	8.0	8.1	-2.1	10.5	-10.1	-17.4	9.6	16.3	28.5
+ Deferred Tax	0.0	88.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Expense	0.0	88.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	-275.3	-255.5	-13.5	8.0	8.1	-2.1	10.5	-10.1	-17.4	9.6	16.3	28.5
+ Net Income — Continuing Ops	-275.3	-255.5	-13.5	8.0	8.1	-2.1	10.5	-10.1	-17.4	9.6	16.3	28.5
+ Other Comprehensive Income	-0.0	0.3	-0.0	1.7	-0.1	-0.6	-0.0	0.8	1.6	0.5	-0.1	0.1
Total Comprehensive Income	-275.4	-255.2	-13.5	9.7	8.0	-2.7	10.5	-9.3	-15.9	10.1	16.3	28.6
Net Income to Common	-275.3	-255.3	-13.5	—	8.1	-2.1	10.5	-10.1	-17.4	9.6	16.3	28.5
Minority Interest	0.0	-0.1	0.0	—	0.0	-0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per Share
Basic EPS	-76.49	-70.93	-3.50	2.54	2.03	-0.93	2.46	-2.36	-3.98	2.20	3.52	5.92
Diluted EPS	-76.49	-70.93	-3.50	2.54	2.03	-0.93	2.46	-2.36	-3.98	2.20	3.52	5.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.6	-0.0	0.8	1.6	0.5	-0.1	0.1
+ Items NOT to be Reclassified to P&L	0.0	0.3	—	1.7	0.0	-0.6	—	1.0	1.6	0.7	—	0.2
+ Items to be Reclassified to P&L	-0.0	-0.0	-0.0	-0.0	-0.1	0.0	—	-0.2	-0.1	-0.2	-0.1	-0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	-275.4	-255.0	-13.5	—	8.0	-2.7	10.5	-9.3	-15.9	10.1	16.3	28.6
Comprehensive Income — Non-controlling Interests	0.0	-0.1	0.0	—	0.0	-0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	-76.49	-70.93	-3.50	2.54	2.03	-0.93	2.46	-2.36	-3.98	2.20	3.52	5.92
Diluted EPS — Continuing Operations	-76.49	-70.93	-3.50	2.54	2.03	-0.93	2.46	-2.36	-3.98	2.20	3.52	5.92
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	33.2	139.5	161.9	175.1	165.5	154.9	172.7	159.5	162.4	189.9	185.2	203.7
Gross Margin %	13.35	46.57	44.55	50.46	55.09	56.75	54.11	50.88	46.53	49.02	48.52	48.80
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-212.6	-44.5	-13.5	8.0	8.1	-2.1	10.5	-10.1	-10.7	8.7	16.3	33.0
− Exceptional Items (reconciliation)	-62.8	-122.2	0.0	0.0	0.0	0.0	0.0	0.0	-6.8	0.9	0.0	-4.5
Net Income Adj (tax-effected)	-212.6	-133.3	-13.5	8.0	8.1	-2.1	10.5	-10.1	-10.7	8.7	16.3	33.0
EPS Adj	-59.05	-37.00	-3.50	2.54	2.03	-0.93	2.46	-2.36	-2.44	2.00	3.52	6.86
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	36.0	36.0	40.2	40.2	40.3	40.3	44.3	44.5	44.5	44.5	48.1	48.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Solara Active Pharma Sciences Q2 FY27 results (July–September 2026)

Filed with NSE on Friday, 16 October 2026 at 1:36 pm IST

Solara Active Pharma Sciences (NSE: SOLARA) reported its Q2 FY27 results (July–September 2026) on Friday, 16 October 2026 at 1:36 pm IST. Consolidated net profit was ₹28.5 crore, against a loss of ₹10.1 crore in Q2 FY26 and up 74.5% from ₹16.3 crore in Q1 FY27. Revenue from operations was ₹417 crore, up 33.1% year on year and up 9.4% from the previous quarter.

Q2 FY26 results (a year earlier): 5 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹28.5 Crloss ₹10.1 Cr in Q2 FY26+74.5% vs Q1 FY27
Revenue from operations: ₹417 Cr+33.1% vs Q2 FY26+9.4% vs Q1 FY27
Operating margin (EBIT): 12.0%+8.8 pts vs Q2 FY26+2.8 pts vs Q1 FY27EBIT ₹50.2 Cr
EBITDA: ₹76.8 Cr+121.2% vs Q2 FY26+24.0% vs Q1 FY27margin 18.4%
Earnings per share (basic): ₹5.92+68.2% vs Q1 FY27
Net profit margin: 6.8%+10.0 pts vs Q2 FY26+2.5 pts vs Q1 FY27

Questions

What was Solara Active Pharma Sciences' net profit in Q2 FY27?

Consolidated net profit was ₹28.5 crore, against a loss of ₹10.1 crore in Q2 FY26 and up 74.5% from ₹16.3 crore in Q1 FY27.

What was Solara Active Pharma Sciences' revenue in Q2 FY27?

Revenue from operations was ₹417 crore, up 33.1% year on year and up 9.4% from the previous quarter.

What was Solara Active Pharma Sciences' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹44.8 crore. Revenue from operations was ₹799 crore, up 26.3%.

How were Solara Active Pharma Sciences' Q2 FY27 results?

A net profit of ₹28.5 crore, against a loss of ₹10.1 crore in Q2 FY26. Revenue was up 33.1% at ₹417 crore. The operating margin was 12.0%, up 8.8 percentage points from 3.3% a year earlier. Against Q1 FY27, net profit was up 74.5% and revenue up 9.4%.

What was Solara Active Pharma Sciences' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹50.2 crore, a margin of 12.0%, against 9.2% in Q1 FY27 and 3.3% in Q2 FY26. EBITDA was ₹76.8 crore, 18.4% of revenue.

What was Solara Active Pharma Sciences' revenue in FY26?

Revenue from operations was ₹1,369 crore in FY26 (April 2025–March 2026), up 6.6% from ₹1,284 crore in FY25. It was ₹1,289 crore in FY24 and ₹1,444 crore in FY23: down 5.2% over three years, an average fall of 1.8% a year.

What was Solara Active Pharma Sciences' EPS in Q2 FY27?

Basic earnings per share were ₹5.92.

What is Solara Active Pharma Sciences' net profit margin?

Solara Active Pharma Sciences' net profit margin was 6.8% in Q2 FY27 (net profit as a share of revenue from operations), against −3.2% in Q2 FY26 (up 10.0 percentage points). For FY26 as a whole it was −0.5%.

When did Solara Active Pharma Sciences announce its Q2 FY27 results?

On Friday, 16 October 2026 at 1:36 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 5 November 2025.

How has Solara Active Pharma Sciences' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹17.4 crore in Q3 FY26, a profit of ₹9.6 crore in Q4 FY26, a profit of ₹16.3 crore in Q1 FY27 and a profit of ₹28.5 crore in Q2 FY27. That is a combined profit of ₹36.9 crore over the four quarters, up 476.3% from ₹6.4 crore in the four quarters before. Revenue from operations: ₹349 crore, ₹387 crore, ₹382 crore and ₹417 crore.

What was Solara Active Pharma Sciences' net profit in FY26?

Consolidated net profit was a loss of ₹7.4 crore in FY26 (April 2025–March 2026), against a profit of ₹54 lakh in FY25. It was a loss of ₹567 crore in FY24 and a loss of ₹22.2 crore in FY23.

When will Solara Active Pharma Sciences announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Solara Active Pharma Sciences figures come from?

From Solara Active Pharma Sciences' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 16 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.